Skip to main content
Caplight Logo









Arbele Limited

Arbele Limited

Private
Hong KongHealthcare & Life Scienceshttps://www.arbelebio.com/

Last Round

Seed

Apr 7, 2021

Total Funding Raised

$428,000

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Arbele Limited is a biotechnology company that develops multi-specific antibody therapeutics, antibody-drug conjugates (ADCs), and cell therapies for treating gastrointestinal cancers.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Application

Keywords

cancer immunotherapygastrointestinal cancerGI cancerCDH17 biomarkerclinical stage biotechantibody drug conjugateADCbispecific antibodyT-cell engageroncology drug developmentCAR-T therapypancreatic cancercell therapycompanion diagnosticsCAR-NK therapydrug co-development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Arbele Limited Comparables

Compare Arbele Limited with similar companies based on industry and business-model similarity.

Arbele Limited comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Biosion, Inc.
84%
BioRay Pharmaceutical Co., Ltd.
82%
Chimeric Therapeutics Limited
80%

Arbele Limited Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedApr 7, 2021

Key People

Founding team and executive leadership

Chun Fung Chan

Chief Technology Officer

Executive Team

Arbele Limited Investors

Notable investors and investment history

Arbele Limited investors
InvestorRounds
Asian Fund for Cancer ResearchSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 26, 2026

    Monthly visitors grew 168% MoM, from 407 to 1.1K.

  • Feb 12, 2026

    Grew 25% QoQ, from 16 to 20 employees.

Arbele Limited Filings

Explore SEC and related filing metadata, where available.

Arbele Limited filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Arbele Limited's valuation, stock price, and market status.

Is Arbele Limited a public or private company?

Arbele Limited is a private company.

What is the current stock price of Arbele Limited?

Arbele Limited is a private company with no public stock price. No recent secondary market data is available.

How much is Arbele Limited worth (valuation)?

Valuation information for Arbele Limited is not publicly available.

Can I buy Arbele Limited stock?

Arbele Limited shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Arbele Limited's last funding round?

Funding round information for Arbele Limited is not publicly available.

Who are the main investors in Arbele Limited?

Investor information for Arbele Limited is not publicly disclosed.

Will Arbele Limited IPO soon?

No public IPO plans have been announced for Arbele Limited.

How can I track Arbele Limited secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Arbele Limited's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersHong Kong
Employee Range11
Year Founded2016
Last FundingApr 7, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?